BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Rosiglitazone
,
rs3825942
,
GATA1
,
Response to oxidative stress
,
HIV infection
,
Biofuel
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
MC38
Summary
General Info
Curated Studies
Most Correlated Studies
S100A8/A9 treatment in colon cancer cell line MC38
Kidney, lung, tumor, liver, muscle & heart of mice with MC38 tumor treated with anti-PD-1 & CTLA-4
Liver metastases of colon cancer cells in myeloid cell depleted mice
Colorectal cancer biopsies from patients stratified by stage, recurrence, and survival
Explore Curated Studies Results
Literature
Most Relevant Literature
A syngeneic MC38 orthotopic mouse model of colorectal cancer metastasis.
Combined effects of exercise and immuno-chemotherapy treatments on tumor growth in MC38 colorectal c…
MC38 Tumors Induce Musculoskeletal Defects in Colorectal Cancer.
Late-stage MC38 tumours recapitulate features of human colorectal cancer - implications for appropri…
Combination treatment with 17β-estradiol and anti-PD-L1 suppresses MC38 tumor growth by reducing PD-…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSC…
Cancer Vaccine Targeting Brachyury Protein in Tumors
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ